CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 24.75×, higher than 95% of its Biotechnology peers (median 5.5×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.71BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.00xvs all stocks
52-Week Change
179.62%vs all stocks
Market Capitalization
2.71BUSDvs all stocks (USD)
Enterprise Value
2.54BUSDvs all stocks (USD)
Forward P/E
-34.19xvs Biotechnology peers
Price to Book (MRQ)
14.23xvs Biotechnology peers
Enterprise to EBITDA
-48.20xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-23.02%vs Biotechnology peers
Return on Equity (TTM)
-33.59%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-52.63MUSDvs all stocks (USD)
Net Income (TTM)
-45.61MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-45.30MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-28.53MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-49.33MUSDvs all stocks (USD)
Pre-tax Income
-42.82MUSDFY2025 · Dec 31, 2025Income Tax Expense
-64.00KUSDFY2025 · Dec 31, 2025Net Income
-42.76MUSDFY2025 · Dec 31, 2025EBIT
-42.82MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-42.68MUSDFY2025 · Dec 31, 2025Research & Development
33.48MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
15.85MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.54MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-42.76MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-37.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-37.58MUSDDerived from operating cash flow minus capital expenditure. This filing charges 144K of depreciation against 12K of capital expenditure, and its own free-cash-flow line reads -42.1M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
18.91MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-42.76MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
144.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.18MUSDFY2025 · Dec 31, 2025Other Non-cash Items
463.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-598.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-12.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-170.66MUSDFY2025 · Dec 31, 2025Sale of Investments
76.57MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-94.11MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-11.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-84.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
108.06MUSDFY2025 · Dec 31, 2025Shares Outstanding
128.41MSharesUpdated Jul 19, 2026Float Shares
118.77MSharesUpdated Jul 19, 2026Shares Short
13.87MSharesUpdated Jul 19, 2026Short Ratio
6.33daysvs all stocks
Short % of Shares Outstanding
10.85%vs all stocks
% Held by Insiders
0.63%vs all stocks
% Held by Institutions
99.29%vs all stocks
Total Cash (MRQ)
171.78MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.21USDUpdated Jul 19, 2026Total Debt (MRQ)
682.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0040xvs Biotechnology peers
Current Ratio (MRQ)
24.75xvs Biotechnology peers
Book Value per Share (MRQ)
1.34USDUpdated Jul 19, 2026Total Assets
193.44MUSDvs all stocks (USD)
Total Current Assets
191.66MUSDFY2025 · Dec 31, 2025Total Liabilities
10.20MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.78MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
446.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.75MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
18.91MUSDFY2025 · Dec 31, 2025Other Short-term Investments
169.35MUSDFY2025 · Dec 31, 2025Accounts Payable
3.91MUSDFY2025 · Dec 31, 2025Short-term Debt
307.00KUSDFY2025 · Dec 31, 2025Long-term Debt
446.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
128.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-329.80MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
183.24MUSDvs all stocks (USD)
52-Week Low
6.55USDUpdated Jul 19, 202652-Week High
20.22USDUpdated Jul 19, 202652-Week Change
179.62%vs all stocks
Beta
1.00xvs all stocks
50-Day MA
15.72USDUpdated Jul 19, 2026200-Day MA
12.75USDUpdated Jul 19, 2026Avg 10-Day Volume
3.31MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.72MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.3500USDUpdated Jul 19, 2026Other Income / Expense
-31.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 24.75×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 24.75Industry median: 5.50Industry P95: 22.03Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.78
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $2.71B, above the global median of $1.15BNotable
Market cap (USD): 2,707,553,031Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Maravai Lifesciences Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sinocelltech Group Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
uniQure N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Relay Therapeutics Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration
Zhuzhou Hongda Electronics Co., Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration
Tango Therapeutics Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration